Process for preparing N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]- 4-pyrimidinyl)-N’-propylsulfamide and intermediates thereof
Publication Date: 2014-Jan-21
Publishing Venue
The IP.com Prior Art Database
The following operators can be used to better focus your queries.
( ) , AND, OR, NOT, W/#
? single char wildcard, not at start
* multi char wildcard, not at start
"..." literal
Examples:
(Cat? OR feline) AND NOT dog?
Cat? W/5 behavior
(Cat? OR feline) AND traits
Cat AND charact*
This guide provides a more detailed description of the syntax that is supported along with examples.
This search box also supports the look-up of an IP.com Digital Signature (also referred to as Fingerprint); enter the 72-, 48-, or 32-character code to retrieve details of the associated file or submission.
For a concept search, you can enter phrases, sentences, or full paragraphs in English. For example, copy and paste the abstract of a patent application or paragraphs from an article.
Concept search eliminates the need for complex Boolean syntax to inform retrieval. Our Semantic Gist engine uses advanced cognitive semantic analysis to extract the meaning of data. This reduces the chances of missing valuable information, that may result from traditional keyword searching.
The IP.com Prior Art Database
Undisclosed
English (United States)
Page 01 of 11
Process for preparing N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]- 4-pyrimidinyl)-N'-propylsulfamide and intermediates thereof
N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl)-N'- propylsulfamide referred herein as Compound I has the following Chemical structure:
Provided herein are processes for preparing Compound I and intermediates thereof.
Lithium N-propylsulfamide
Example 1: Process for preparing lithium N-propylsulfamide
N-propylsulfamide (69.1 g, 0.5mol) was dissolved at RT in MTBE (600 ml).The insoluble part was removed by filtration (0.25 g white powder). Water (0.3 ml) was added to the solution. Lithium amide (11.48 g) was added in portions at 15-20 °C. The mixture was stirred overnight at RT. The salt was collected by filtration, washed with MTBE (200ml +100 ml) and dried at 40 °C, 100 mbar overnight to obtain lithium N-propylsulfamide (64.03 g).
1H-NMR (DMSO-d6) δ 0.82 (t, J=7.5 Hz,3H), 1.39 (m, 2H), 2.71 (t, J= 7.5 Hz, 2H), 3.34 (br,
2H); 13C-NMR (DMSO-d6) δ 11.9, 22.8, 45.4.
Figure 1: X-ray powder diffraction (XRPD) pattern of lithium N-propylsulfamide
Intensity (counts)
90000
62500
40000
22500
10000
2500
0
5 10 15 20 25 30 35 40 2Theta (°)
Page 02 of 11
According to figure 1, the crystalline form of lithium N-propylsulfamide is characterized by XRPD peaks at: 5.9, 11.8, 17.7, 18.8, 20.7, 21.4, 22.3, 23.6, 25.4, 27.0, 29.1,
29.4, 29.7, 31.4, 32.2, 34.0, 35.8, 36.4 and 39.1 degrees two theta ±0.2 degrees two theta.
Sodium N-propylsulfamide
Example 2: Process for preparing Sodium N-propylsulfamide
N-Propylsulfamide (13.82 g, 100 mM) was dissolved in 2-propanol (140 ml). While stirring and cooling under nitrogen at room temperature, sodium hydroxide (4.2 g, 105 mM) was added to the solution, and the mixture was stirred at room temperature for 2 h and at 0 - 10 °C for 30 min. The mixture was diluted with THF (20 ml), the precipitated solid was collected by filtration, washed with THF (2 x 20 ml) and dried in reduced pressure at 35 °C to yield Sodium N-propylsulfamide (14.91 g); MS (ES) [M+H]+= 161.039; 1H-NMR (DMSO-d6) δ 0.84 (t, J=7.5 Hz,3H), 1.40 (m, 2H), 2.73 (t, J= 7.5 Hz, 2H), 3.09 (br, 2H).
Figure 2: XRPD pattern of sodium N-propylsulfamide
According to figure 2, the crystalline form of sodium N-propylsulfamide is characterized by XRPD peaks at: 5.3, 5.6, 6.3, 11.1, 12.7, 16.2, 16.6, 18.7, 19.8, 21.1, 21.4,
21.9, 22.2, 23.3, 24.3, 24.7, 25.4, 27.2, 27.9, 28.2, 29.4, 31.9, 33.4 and 34.3 degrees two theta ±0.2 degrees two theta.
Page 03 of 11
Figure 3: FTIR of sodium N-propylsulfamide
80
75
70
65
%Transmittance
60
55
50
45
40
35
30
3500
3000
2500
2000
1500
1000
500
Wavenumbers (cm-1)
N-5-(4-bromophenyl)-6-chloro-4-pyrimidinyl)-N'-propylsulfamide
Example 3: Process for preparing N-5-(4-bromophenyl)-6-chloro-4-pyrimidinyl)-N'-
propylsulfamide
5-(4-Bromophenyl)-4,6-dichloropyrimidine (3.04 g, 10 mM) was dissolved in DMSO (20 ml) while stirring at room temperature...